Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

18-100 years

Phase:

PHASE2

Brief Summary

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Detailed Description

This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD. ...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria of the master protocol:
  • Able and willing to sign the informed consent (IC)
  • Patients with a diagnosis of AD and onset of disease for at least 1 year
  • Moderate to severe AD
  • Key Exclusion Criteria of the master protocol:
  • Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
  • Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
  • Participant with any other active inflammatory skin disease
  • Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
  • Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
  • Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements

Exclusion

    Key Trial Info

    Start Date :

    May 16 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 22 2028

    Estimated Enrollment :

    224 Patients enrolled

    Trial Details

    Trial ID

    NCT06947993

    Start Date

    May 16 2025

    End Date

    December 22 2028

    Last Update

    December 22 2025

    Active Locations (99)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 25 (99 locations)

    1

    Novartis Investigative Site

    Birmingham, Alabama, United States, 35233

    2

    Novartis Investigative Site

    Birmingham, Alabama, United States, 35244

    3

    Novartis Investigative Site

    Fort Smith, Arkansas, United States, 72916

    4

    Novartis Investigative Site

    Fountain Valley, California, United States, 92708